Stocks
Goldman Sachs Upgrades Abivax to Strong-Buy Amid Analyst Optimism
Abivax (NASDAQ:ABVX) has received an upgrade to 'strong-buy' from The Goldman Sachs Group, according to a research note issued on Wednesday by Zacks. This rating change is part of a broader trend in analyst views on Abivax stock.
In recent weeks, several analysts have weighed in on Abivax. Wedbush increased its price objective on the company to $110.00 and gave it a 'neutral' rating. Citizens Jmp reaffirmed a 'market outperform' rating with a target price of $187.00. Meanwhile, Weiss Ratings reiterated a 'sell (d-)' rating.
The current consensus among analysts is for a 'Moderate Buy' rating on Abivax stock, with a consensus target price of $156.38. This is based on data from MarketBeat.com and reflects the views of multiple analyst firms.